#USA #New York #Faruqi & Faruqi #James Wilson #Jasper Therapeutics

Attention Investors of Jasper Therapeutics

Faruqi & Faruqi, LLP, a prominent national securities law firm, has initiated an investigation into potential claims on behalf of investors who experienced losses with Jasper Therapeutics, Inc. (NASDAQ: JSPR). This examination follows events reported from November 30, 2023, to July 3, 2025. Investors are urged to action in light of the class action lawsuit that has been filed against the company.

Why This Matters

The current investment climate necessitates vigilance among shareholders. Faruqi & Faruqi's Securities Litigation Partner, James (Josh) Wilson, has emphasized the importance of communication from investors who have faced significant losses. If you bought or acquired Jasper's securities during the highlighted period, you may have the right to seek recovery for your losses. To discuss your options directly, you can reach out to Josh Wilson at 877-247-4292 or 212-983-9330, ext. 1310.

Allegations Against Jasper Therapeutics

The firm’s investigation centers on serious allegations against Jasper Therapeutics. The complaint claims that the company, along with certain executives, violated federal securities laws by making misleading statements that did not reflect the actual condition of their manufacturing processes. Specifically, it is alleged that:

1. Jasper lacked the necessary controls to ensure that third-party manufacturers were compliant with the required standards for clinical trial materials.
2. This failure increased risks that the outcomes of ongoing research would be compromised, diminishing the regulatory and commercial prospects of the company’s flagship product, briquilimab.
3. The consequences have led Jasper to implement drastic measures to cut costs and extend its operational runway, despite previously asserting a stable financial position.

It is crucial for affected investors to understand that these claimed misstatements could significantly impact the company’s valuation and investor outcomes.

Recent Developments and Responses

On July 7, 2025, Jasper Therapeutics disclosed concerning results from their BEACON Study, acknowledging confounding issues due to a specific drug product lot. The announcement highlighted:

• - An unexpected problem with the drug lot affected clinical trial results.
• - A halt in the development of briquilimab for certain applications, redirecting company focus away from projects previously considered viable.
• - Planned cost-cutting measures, including potential restructuring, were introduced—contradicting earlier claims of financial robustness.

Reacting to this announcement, Jasper's stock witnessed a sharp decline of 55.1%, closing at $3.04 per share—a significant loss for shareholders, who must now navigate the implications of these revelations.

Join the Class Action

The court's role in appointing a lead plaintiff is central to advocating for the rights of investors. This individual will have the responsibility and authority to lead the lawsuit on behalf of all those who suffered losses, guided by legal counsel of their choice. It’s essential to note that participating as a lead plaintiff does not diminish the right to financial recovery for those preferring to remain part of the class without leadership responsibilities.

Faruqi & Faruqi welcomes information from all stakeholders, including whistleblowers, former employees, and other individuals who may have insights regarding Jasper’s conduct. Your voice matters in this matter.

How to Get Involved

If you are an investor in Jasper Therapeutics and would like to learn more or take action, visit www.faruqilaw.com/JSPR for comprehensive information about the class action lawsuit, or contact James Wilson directly at the numbers provided. Keeping up with updates via platforms such as LinkedIn, X (formerly Twitter), and Facebook is also encouraged to stay informed.

Conclusion

This developing situation underscores the critical importance of shareholders remaining informed and proactive. Faruqi & Faruqi stands ready to assist investors seeking justice and accountability from Jasper Therapeutics, reaffirming its commitment to investor rights since its inception. Don’t miss the November 18, 2025, deadline to seek your rightful claims. Act now to protect your investments.

• ---

Note

This communication is classified as attorney advertising and does not guarantee a specific outcome for future cases.